Loading...
XNAS
ABSI
Market cap1.29bUSD
Jul 24, Last price  
7.56USD
1D
-6.32%
1Q
91.88%
IPO
-66.97%
Name

Absci Corp

Chart & performance

D1W1MN
XNAS:ABSI chart
P/E
P/S
457.38
EPS
Div yield, %
Shrs. gr., 5y
8.20%
Rev. gr., 5y
-10.14%
Revenues
3m
-38.24%
2,060,0004,780,0004,782,0005,747,0005,718,0004,534,0002,800,000
Net income
-115m
L+11.71%
-6,584,000-14,353,000-100,960,000-104,904,000-110,566,000-103,106,000-115,183,000
CFO
-93m
L+28.35%
-6,032,000-10,970,000-60,598,000-81,339,000-64,636,000-72,402,000-92,925,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
IPO date
Jul 22, 2021
Employees
193
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT